Needham & Company Cuts Price Target on AtriCure (ATRC) to $20; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
AtriCure Reports Second Quarter 2016 Financial Results
August 4, 2016 4:01 PM EDTRevenue of $39.7 million up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million up 19.9% International sales of $8.8 million up 28.7% as reported, 27.4% constant currency
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2016 financial results.
We are pleased to report second quarter results which reflect many accomplishments we launched two new products, made progress with our clinical trials and made strides in... More
